FDA moving to 'risk-based' inspections even as valsartan scare adds new wrinkle to oversight
FDA inspections of generic drug plants are on the rise and should continue to increase through 2019, Commissioner Scott Gottlieb said this week in a series of tweets. But the game has changed, Gottlieb pointed out, with the number of pre-approval inspections growing more than surveillance inspections, in part to approve more generics in an effort… Read More »